Johnson & Johnson beat third-quarter estimates and raised its 2026 outlook, yet the shares fell as investors focused on two less comfortable facts: a large talc-related charge and slowing growth in medical devices.
Reported sales rose 5.9% to $25.4 billion. Adjusted earnings were $2.59 per share, above the $2.53 consensus cited in the source. GAAP earnings were only $0.09 per share because the quarter included a $5.52 billion pretax litigation charge, mainly tied to J&J's proposed $5.5 billion resolution of remaining ovarian talc claims.
The settlement is not final
The proposed resolution still requires 95% of eligible claimants to opt in. J&J has said no more than $3 billion would be paid in 2027. That makes the charge economically important but different from a completed cash payment. Investors must distinguish an accounting provision and proposed settlement from a final resolution of every talc liability.
MedTech lost momentum
MedTech revenue grew 2.5% from a year earlier to $8.64 billion, down from 7.7% growth in the first quarter and 4.6% in the second. Revenue also declined from $8.93 billion in the prior quarter. Management cited disruption in the Middle East, European budget pressure and pricing pressure in China, while Abiomed's Impella heart pumps remained weak.
Innovative Medicine carried more of the quarter. Pharmaceutical sales rose 7.7% to $16.76 billion, led by Tremfya. The segment now represents roughly two-thirds of company revenue, increasing the importance of drug launches and pipeline execution while the device business works through regional and product-specific pressure.
Guidance moved only modestly. The sales midpoint increased to $101.2 billion from $101.1 billion, while adjusted EPS guidance rose to $11.10 from $11.04. The raise confirms that management expects the full-year business to remain resilient, but it does not erase the MedTech deceleration.
The investment question is therefore broader than whether adjusted earnings beat consensus. J&J needs to show that MedTech growth can reaccelerate and that the talc proposal converts into a durable legal resolution. Until then, the pharmaceutical portfolio supports earnings, while devices and litigation limit how much confidence investors can place in the headline beat.